Company: INSP
Filing Date: 2025-08-04
Form Type: 10-Q
Source: 0001609550-25-000032
Chunk: 89

Company: Inspire Medical Systems, Inc.
Filing Date: 2025-08-04
Form: 10-Q
Item: Part I, Item 8
Chunk 89
---
 results using consolidated net income (loss) and operating income (loss). The monitoring of budget versus actual results are used in establishing management's compensation. The measure of segment assets is reported on the balance sheet as total consolidated assets.

25

Table of ContentsINSPIRE MEDICAL SYSTEMS, INC. NOTES TO CONDENSED FINANCIAL STATEMENTS (Unaudited) (Table amounts in thousands, except share and per share amounts)

Three Months EndedSix Months EndedJune 30,June 30,2025202420252024Revenue$217,086 $195,885 $418,403 $359,895 Less: (a)Cost of goods sold34,672 29,843 65,381 54,600 Research and development expense26,209 28,859 54,012 57,709 Selling, general and administrative expense (excluding advertising expense)134,806 108,868 258,155 208,885 Advertising expense24,715 23,216 45,656 48,820 Operating (loss) income(3,316)5,099 (4,801)(10,119)Other income (b)(984)(5,747)(6,628)(11,610)Income taxes1,260 1,053 2,427 1,703 Segment net income (loss)(3,592)9,793 (600)(212)Reconciliation of profit or lossAdjustments and reconciling items— — — — Consolidated net income (loss)$(3,592)$9,793 $(600)$(212)(a) The significant expense categories and amounts align with the segment-level information that is regularly provided to our chief operating decision maker.(b) Other income represents the consolidated amounts for interest and dividend income, interest expense, and other expense, net, as shown on our consolidated statements of operations and comprehensive income (loss). For the three-month periods ended June 30, 2025 and 2024, depreciation and amortization expense was $3.4 million and $1.4 million, respectively, and for the six-month periods ended June 30, 2025 and 2024, depreciation and amortization expense was, $6.5 million and $2.2 million, respectively, and is included within the segment expense captions of cost of goods sold, research and development expense, and selling, general and administrative ("